Agios Pharmaceuticals, Inc.
Nasdaq AGIO · Cambridge, MA
Works in Genetic & rare · Hematology · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Women's health
Agios Pharmaceuticals, Inc. is a clinical trial sponsor based in Cambridge, MA, listed as Nasdaq AGIO. It has 16 active clinical trials with 2,089 planned participants, across 7 therapeutic areas. Since 2021 it has completed 13 trials and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq AGIO
Pipeline · 16 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Agios Pharmaceuticals, Inc
Agios Pharmaceuticals, Inc is lead sponsor of 16 active clinical trials on ClinicalTrials.gov, with 2,089 planned participants, in Genetic & rare, Hematology, Metabolic & endocrine, Neurology and other areas. Since 2021 it has completed 13 trials and stopped 2 early.
Agios Pharmaceuticals, Inc is based in Cambridge, MA and is listed as Nasdaq AGIO. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Agios Pharmaceuticals, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Agios Pharmaceuticals, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.